Glenmark Pharmaceuticals Launches Drug To Treat Heart Failure In India

Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure with HFrEF

Topics

Glenmark Pharmaceuticals | Pharma Companies | Heart Failure

Press Trust of India  |  New Delhi 



Glenmark Pharmaceuticals

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();

on Tuesday said it has launched sacubitril and valsartan combination tablets in India for treatment of .

The prescription drug has been launched under brand 'Sacu V' and is priced at Rs 19 per tablet for a dose of 50mg (sacubitril 24mg + valsartan 26mg), Rs 35 per tablet for a dose of 100mg (sacubitril 49mg + valsartan 51mg), and Rs 45 per tablet for a dose of 200mg (sacubitril 97mg + valsartan 103 mg), Glenmark said in a regulatory filing.

EVP & Business Head India Formulations, Alok Malik said Sacu V is an advanced and affordable treatment option, which has been shown to reduce the risk of cardiovascular death or hospitalisation and to improve symptoms associated with with reduced ejection fraction (HFrEF).

The company said Sacu V must be taken twice daily under doctor's prescription. Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure with HFrEF.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

First Published: Tue, January 17 2023. 14:41 IST


RECENT NEWS

Revoluts Australian Banking Licence Game Changer

Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more

The AI Bank Is Coming, But Who Controls The Risk?

Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more

ClearBank UK Profit Leads To European Growth

ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more

Bank Of London Continues To Rebuild

ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more

JPMorgan's Berlin Moment: Chase Takes On Europe

There is something quietly symbolic about JPMorgan Chase choosing Berlin as its gateway into continental Europe. In a fo... Read more

What Strategy's Bitcoin Sale Really Tells Us

There is a moment in every bull run when the narrative starts to fray. Not with a crash, not with a scandal, but with so... Read more